Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment

@inproceedings{Braa2012ClinicalDO,
  title={Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment},
  author={Irene Bra{\~n}a and Lillian L Siu},
  booktitle={BMC Medicine},
  year={2012}
}
The phosphatidylinositol 3-kinase (PI3K) pathway is commonly deregulated in cancer. In recent years, the results of the first phase I clinical trials with PI3K inhibitors have become available. In comparison to other targeted agents such v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors in melanoma or crizotinib in anaplastic lymphoma receptor tyrosine kinase (ALK) translocated tumors, the number of objective responses to PI3K inhibitors is less dramatic. In this review we… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 51 CITATIONS, ESTIMATED 57% COVERAGE

Genetics of Gastric Cancer.

  • The Surgical clinics of North America
  • 2017
VIEW 2 EXCERPTS
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2013
2019

CITATION STATISTICS

  • 1 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 146 REFERENCES

A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2012
VIEW 1 EXCERPT

A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer [abstract

IE Krop, C Saura, +10 authors J Baselga
  • ASCO Annual Meeting Proceedings: June
  • 2012

A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer [abstract

IE Krop, C Saura, +10 authors J Baselga
  • ASCO Annual Meeting Proceedings: June
  • 2012

Similar Papers

Loading similar papers…